Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ekso Bionics Holdings (EKSO) Accounts Payables (2016 - 2025)

Ekso Bionics Holdings (EKSO) has disclosed Accounts Payables for 13 consecutive years, with $1.4 million as the latest value for Q4 2025.

  • On a quarterly basis, Accounts Payables fell 7.8% to $1.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.4 million, a 7.8% decrease, with the full-year FY2025 number at $1.4 million, down 7.8% from a year prior.
  • Accounts Payables was $1.4 million for Q4 2025 at Ekso Bionics Holdings, down from $1.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $3.2 million in Q2 2023 to a low of $1.3 million in Q3 2021.
  • A 5-year average of $2.1 million and a median of $1.9 million in 2024 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: skyrocketed 107.0% in 2021, then crashed 41.38% in 2023.
  • Ekso Bionics Holdings' Accounts Payables stood at $3.1 million in 2021, then rose by 1.42% to $3.2 million in 2022, then plummeted by 41.38% to $1.8 million in 2023, then dropped by 15.97% to $1.6 million in 2024, then decreased by 7.8% to $1.4 million in 2025.
  • Per Business Quant, the three most recent readings for EKSO's Accounts Payables are $1.4 million (Q4 2025), $1.7 million (Q3 2025), and $1.4 million (Q2 2025).